This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

As obesity rates in the United States have reached 41.9 percent among adults, Xevant has released a new e-book, Navigating Obesity Care and GLP-1 Coverage: A Guide for Employers, designed to empower ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...

From loss of skin elasticity to hair density, supplements that offer targeted support for GLP-1 users, as well as those that ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...

Ozempic doesn't just reduce weight. Research shows GLP-1s also changes how much people spend on food, and the types of food ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...